| Q91403427 | 8p deletions in renal cell carcinoma are associated with unfavorable tumor features and poor overall survival |
| Q38833458 | Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. |
| Q53519887 | Association of ERG and TMPRSS2-ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels. |
| Q37474443 | Biomarkers for prostate cancer: present challenges and future opportunities |
| Q92316366 | Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications |
| Q49964150 | Clinical Utility and Biologic Implications of Phosphatase and Tensin Homolog (PTEN) and ETS-related Gene (ERG) in Prostate Cancer |
| Q49818398 | Clinical implications of PTEN loss in prostate cancer |
| Q87176751 | Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger |
| Q38356863 | Clinically relevant genetic characterization of prostate tumors: how close are we to the goal? |
| Q38774228 | DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer |
| Q57230540 | Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer |
| Q38681610 | ERG expression in prostate cancer: biological relevance and clinical implication |
| Q34722101 | Genomic rearrangements in prostate cancer |
| Q90669489 | High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer |
| Q91632368 | Is There Etiologic Heterogeneity between Subtypes of Childhood Acute Lymphoblastic Leukemia? A Review of Variation in Risk by Subtype |
| Q39117370 | Is There a Role for Genetic Information in Risk Assessment and Decision Making in Prostate Cancer? |
| Q38778266 | Molecular subtyping of prostate cancer |
| Q39401816 | PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer |
| Q41907553 | PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas |
| Q42371556 | PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort |
| Q59136276 | Predictive significance of - fusion in prostate cancer: a meta-analysis |
| Q37520447 | Presence of TMPRSS2-ERG is associated with alterations of the metabolic profile in human prostate cancer |
| Q92410882 | Prostate Cancer Genomic Subtypes |
| Q52629153 | Prostatic cancers: understanding their molecular pathology and the 2016 WHO classification. |
| Q39342369 | Rationale for the development of alternative forms of androgen deprivation therapy |
| Q92007394 | Retracted: Identification of Prognosis Biomarkers of Prostatic Cancer in a Cohort of 498 Patients from TCGA |
| Q92029365 | TMPRSS2-ERG fusions linked to prostate cancer racial health disparities: A focus on Africa |
| Q26750672 | The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements |
| Q52689045 | The Use of Biomarkers in Prostate Cancer Screening and Treatment. |
| Q38540636 | The genomic evolution of human prostate cancer. |
| Q40281409 | Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment |
| Q26798425 | What is the Need for Prostatic Biomarkers in Prostate Cancer Management? |
| Q38402732 | Young-age prostate cancer. |
| Q94526757 | microRNA Expression Profiling in Young Prostate Cancer Patients |
| Q64240600 | p53 overexpression is a prognosticator of poor outcome in esophageal cancer |